CareDx CDNA Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $379.81M+13.8% | $333.79M+19.1% | $280.32M-12.9% | $321.79M+8.6% | ||
| —— | —— | —— | —— | ||
| $71.43M-1.5% | $72.51M-12.0% | $82.42M-8.8% | $90.39M+18.1% | ||
| $102.64M+25.2% | $81.98M-2.5% | $84.06M-12.5% | $96.03M+24.3% | ||
| $107.57M-14.0% | $125.14M+5.3% | $118.84M+18.4% | $100.4M+33.9% | ||
| $410.59M+40.1% | $293.02M-39.4% | $483.69M+21.2% | $399.02M+22.4% | ||
| -$30.78M-176% | $40.77M+120% | -$203.36M-163% | -$77.23M-160% | ||
| -8.1%-20.3pp | 12.2%+84.8pp | -72.5%-48.5pp | -24%-14.0pp | ||
| $9.17M-22.0% | $11.77M-0.9% | $11.87M+215% | $3.76M+2,251% | ||
| $9.7M-19.8% | $12.09M-8.5% | $13.22M+1,226% | $997K+142% | ||
| -$21.08M-140% | $52.86M+128% | -$190.14M-149% | -$76.23M-138% | ||
| $271K-12.6% | $310K+120% | $141K-62.8% | $379K+127% | ||
| -$21.35M-141% | $52.55M+128% | -$190.28M-148% | -$76.61M-150% | ||
| -5.6%-21.4pp | 15.7%+83.6pp | -67.9%-44.1pp | -23.8%-13.5pp | ||
| -$0.40-143% | $0.93+126% | -$3.53-143% | -$1.45-146% | ||
| -$15.76M-129% | $54.96M+129% | -$188.98M-188% | -$65.64M-214% | ||
| -4.2%-20.6pp | 16.5%+83.9pp | -67.4%-47.0pp | -20.4%-13.3pp | ||
| -$30.78M-176% | $40.77M+120% | -$203.36M-163% | -$77.23M-160% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is CareDx's revenue?
- CareDx (CDNA) generated $412.8M in revenue over the trailing twelve months, up 19.2% year over year.
- Is CareDx profitable?
- CareDx is not currently profitable: it reported a net loss of $8.2M over the trailing twelve months, a -2.0% net margin.
- What are CareDx's profit margins?
- Gross margin is 65.5% and operating margin is -3.9%, with a -2.0% net margin.
- What is CareDx's earnings per share?
- CareDx's diluted EPS over the trailing twelve months is $-0.16.
- Where does CareDx's income statement data come from?
- Every line is extracted from CareDx's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
